Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPY Angiography for Nerve Decompression
NCT05332405Phase 4Withdrawn
- Sponsor
- NYU Langone Health
- Start
- May 2022
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of indocyanine green in Cubital tunnel syndrome (CuTS) and median neuropathy, sponsored by NYU Langone Health. Primary endpoint: Change in level of Fluorescence before and after nerve release. Planned start May 2022; status: withdrawn.
02
Drugs
indocyanine green
03
Conditions
Cubital tunnel syndrome (CuTS)median neuropathy
Beyond the preview
Go deeper on NCT05332405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05332405.